Skip to content

PE and LEER surgical treatment of gynecologic malignant tumor recurrence of her period of preliminary study

PE and LEER surgical treatment of gynecologic malignant tumor recurrence of her period of preliminary study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057501
Enrollment
Unknown
Registered
2022-03-14
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced and recurrent gynecological malignancies

Interventions

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary advanced, recurrent gynecological malignancies (ovarian cancer, endometrial cancer, cervical cancer, etc.) or recurrent gynecological malignancies in the pelvic lateral wall. 2. According to clinical evaluation, surgical treatment can achieve local tumor cure or at least prolong the life of patients. 3. The patient's physical and mental state can withstand the risks of surgery and cope with postoperative complications. 4. There is no equivalent alternative therapy. 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The tumor has been evaluated as distant metastasis by imaging or considered unresectable by physical examination. 2. This operation is planned only for the treatment of disease complications (such as rectovaginal fistula). 3. Lack of histological evidence of gynecological malignancy. 4. Mental illness or mental illness, unable to cooperate with the subjects. 5. Also participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Overall survival;Progression free survival;

Secondary

MeasureTime frame
Tumor biomarks;Imaging evaluation;

Countries

China

Contacts

Public ContactYao Liangqing
yaoliangqing@163.com+86 18002454522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026